Published by the C
International
T
ITIN
Myeloma Foundation
halidomide and RevlimidTM Issue GS
Special Edition : ASH 2004
Welcome to The International Myeloma Foundation's special edition of CITINGS,
our new, quarterly publication featuring the most up-to-date information on myeloma
treatment. In this edition, we continue our focus on thalidomide and RevlimidTM (CC-5013)
and highlight data presentations taking place at the American Society of Hematology (ASH)
Annual Meeting. The IMF has selected key presentations and has listed the date and time of
each to facilitate your scheduling needs.
We hope you will find this to be a useful tool as you enjoy the ASH meeting. We look forward
to hearing your feedback by calling (800)452-CURE or clicking on www.myeloma.org.
--Susie Novis, President, IMF
ASH Presentations
[1482] Primary Treatment with Pulsed Melphalan, Dexamethasone, Thalidomide (MDT) for Symptomatic
Patients with Multiple Myeloma 75 Years of Age. Session Type: Poster Session 636-I
Authors: Meletios A. Dimopoulos, Panagiotis Repoussis, Evangelos Terpos, Maria Christina Kyrtsonis,
Athanasios Zomas, Eirini Katodritou, Souzana Delibasi, Amalia Vassou, Athanasios Anagnostopoulos, Anastasia
Pouli, Konstantinos Zervas, Dimitrios Margaritis, Nikolaos Anagnostopoulos, Alice G. Maniatis
Date/Time: Saturday, December 4, 2004 - 6:00 PM
Session Info: Poster Session: Myeloma Therapy - Non-Transplant I (6:00 PM-7:30 PM)
[205] Thalidomide Plus Dexamethasone Versus Dexamethasone Alone in Newly Diagnosed Multiple
Myeloma (E1A00): Results of a Phase III Trial Coordinated by the Eastern Cooperative Oncology Group.
Session Type: Oral Session
Authors: S. Vincent Rajkumar, Emily Blood, David H. Vesole, Robert Shepard, Philip R. Greipp
Date/Time: Monday, December 6, 2004 - 7:30 AM
Session Info: Simultaneous Session: Myeloma Therapy (7:30 AM-9:00 AM)
[210] VTD (VELCADE, Thalidomide, Dexamethasone) as Primary Therapy for Newly-Diagnosed
Multiple Myeloma.
Session Type: Oral Session
Authors: Raymond Alexanian, Luhua M. Wang, Donna M. Weber, Kay B. Delasalle
Date/Time: Monday, December 6, 2004 - 8:45 AM
Session Info: Simultaneous Session: Myeloma Therapy (7:30 AM-9:00 AM)
www.myeloma.org
(800) 452 - CURE (2873)
Funded by an educational grant from Celgene Corporation
[207] A Prospective Randomized Trial of Oral Melphalan, Prednisone, Thalidomide (MPT) vs Oral
Melphalan, Prednisone (MP): An Interim Analysis.
Session Type: Oral Session
Authors: Antonio Palumbo, Alessandra Bertola, Pellegrino Musto, Tommaso Caravita, Vincenzo Callea,
Clotilde Cangialosi, Anna Marina Liberati, Pasquale Niscola, Lucio Catalano, Mariella Grasso, Vito Michele
Lauta, Maria Concetta Petti, Sergio Morandi, Monica Galli, Sara Bringhen, Federica Cavallo, Patrizia Falco,
Mario Boccadoro
Date/Time: Monday, December 6, 2004 - 8:00 AM
Session Info: Simultaneous Session: Myeloma Therapy (7:30 AM-9:00 AM)
[208] Doxil (D), Vincristine (V), Reduced Frequency Dexamethasone (d) and Revlimid(R) (DVd-R) a Phase
I/II Trial in Advanced Relapsed/Refractory Multiple Myeloma (Rmm) Patients.
Session Type: Oral Session
Authors: Mohamad A. Hussein, Mary Ann Karam, Catherine Brand, Greg L. Pearce, Janice Reed, Kellie
Bruening, Paul Sartori, Gordan Srkalovic, Marta Olesnyckyj, Robert Knight, Kathe Balinski, Jerome Zeldis
Date/Time: Monday, December 6, 2004 - 8:15 AM
Session Info: Simultaneous Session: Myeloma Therapy (7:30 AM-9:00 AM)
[331] Combination Therapy with CC-5013 (Lenalidomide; Revlimid) Plus Dexamethasone (Rev/Dex) for
Newly Diagnosed Myeloma (MM).
Session Type: Oral Session
Authors: S. Vincent Rajkumar, Suzanne R. Hayman, Martha Q. Lacy, Angela Dispenzieri, Antje Hoering,
Susan M. Geyer, Steven R. Zeldenrust, Philip R. Greipp, Rafael Fonseca, John A. Lust, Stephen J. Russell,
Robert A. Kyle, Thomas E. Witzig, Morie A. Gertz
Date/Time: Monday, December 6, 2004 - 11:00 AM
Session Info: Simultaneous Session: Myeloma Therapy Novel Agents (11:00 AM-12:30 PM)
[535] Maintenance Treatment with Thalidomide after Autologous Transplantation for Myeloma: First
Analysis of a Prospective Randomized Study of the Intergroupe Francophone du Myelome (IFM 99 02).
Session Type: Oral Session
Authors: Michel Attal, Jean-Luc Harousseau, Serge Leyvraz, Chantal Doyen, Cyrille Hulin, Lofti Benboubker,
Thierry Facon, Jean-Henri Bourhis, Laurent Garderet, Jean-Jacques Sotto, Mauricette Michallet, Marc Renaud,
Laurent Voillat, Christian Berthou, Gerald Marrit, Mathieu Monconduit, Bertrand Coiffier, Denis Caillo
Date/Time: Monday, December 6, 2004 - 3:30 PM
Session Info: Simultaneous Session: Autologous Stem Cell Transplatation in Multiple Myeloma and
Amyloidosis (3:30 PM-5:30 PM)
www.myeloma.org
(800) 452 - CURE (2873)